Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 35.2% in March

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 5,208 shares, a decline of 35.2% from the February 26th total of 8,036 shares. Based on an average trading volume of 17,617 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.0% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.00.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock opened at $0.55 on Friday. The company has a market capitalization of $22.47 million, a P/E ratio of -0.34 and a beta of -0.63. Barinthus Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.92. The stock has a 50-day simple moving average of $0.65 and a 200-day simple moving average of $0.87.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings results on Friday, March 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.13. As a group, analysts forecast that Barinthus Biotherapeutics will post -1.38 earnings per share for the current year.

Institutional Trading of Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. raised its holdings in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 192,461 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned about 0.48% of Barinthus Biotherapeutics worth $179,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.